iLux Treatment for Meibomian Gland Dysfunction (MGD)

Sponsor
Tear Film Innovations, Inc. (Industry)
Overall Status
Completed
CT.gov ID
NCT03055650
Collaborator
(none)
30
Enrollment
3
Locations
1
Arm
2.4
Actual Duration (Months)
10
Patients Per Site
4.2
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to assess changes in meibomian gland function and evaporative dry eye symptoms after treatment with the iLux medical device.

Condition or DiseaseIntervention/TreatmentPhase
  • Device: iLux 2020 System
N/A

Detailed Description

Alcon Research, LLC, acquired TearFilm Innovations, Inc., in December 2018. This study was designed and conducted by TearFilm Innovations, Inc. The study results were collected, analyzed, and provided by TearFilm Innovations, Inc., to Alcon Research, LLC.

Study Design

Study Type:
Interventional
Actual Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
iLux Treatment for Meibomian Gland Dysfunction (MGD)
Actual Study Start Date :
Dec 7, 2015
Actual Primary Completion Date :
Feb 18, 2016
Actual Study Completion Date :
Feb 18, 2016

Arms and Interventions

ArmIntervention/Treatment
Experimental: iLux 2020 System

Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual

Device: iLux 2020 System
Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands

Outcome Measures

Primary Outcome Measures

  1. Change From Baseline in Meibomian Gland Secretion (MGS) Total Score [Baseline (Day 0 pretreatment), Week 1, Month 1]

    Meibomian glands on the lower eyelid were assessed by the examiner using a Meibomian Gland Evaluator (MGE 1000) device while viewing the eyelid margin with a slit lamp microscope. 5 glands in 3 zones (nasal, medial, temporal) were evaluated. Each gland was scored from 0-3, for a resultant overall score of 0-45 for each eye. MGS scoring was as follows: 0 = no secretion (worst), 1 = inspissated, 2 = cloudy, 3 = clear liquid (best). A positive change value indicates an improvement. Eyes were assessed individually.

  2. Change From Baseline in Tear Break-Up Time (TBUT) [Baseline (Day 0 pretreatment), Week 1, Month 1]

    The investigator instilled a drop of fluorescein into the lower eyelid and asked the patient to blink several times, then stop. The time between the last blink and the first appearance of a dark spot on the cornea (formation of a dry area) on the otherwise continuously stained tear film was recorded in seconds. 3 consecutive measurements were taken, with TBUT defined as the average of the 3 measurements. A positive change value represents A positive change value represents a more stable tear film (improvement). Eyes were assessed individually.

Secondary Outcome Measures

  1. Change From Baseline in Standard Patient Evaluation of Eye Dryness (SPEED) Total Score [Baseline (Day 0 pretreatment), Week 1, Month 1]

    The Standard Patient Evaluation of Eye Dryness (SPEED) survey is a validated survey that assesses both the frequency and severity of dry eye symptoms. The patient grades the frequency of symptoms (4 items) on a scale from 0 to 3 (0=never; 3=constant) and the severity of each symptom (4 items) on a scale from 0 to 4 (0=no problems; 4=intolerable). Responses to the 8 items are summed to calculate a total score ranging from 0 to 28, where 0=best and 28=worst. A negative change value indicates a perceived improvement in ocular health. Both eyes contributed to the mean.

  2. Change From Baseline in Ocular Surface Disease Index (OSDI) Total Score [Baseline (Day 0 pretreatment), Month 1]

    The OSDI is a validated, 12-item questionnaire used to measure ocular symptoms, visual function, and environmental factors that may affect a patient's vision. The patient grades each item on a scale from 0 to 4, where 0 is "None" and 4 is "All of the Time." Responses to the 12 items are summed, and a formula is used to calculate a total score from 0 to 100, where 0 corresponds to no disability and 100 corresponds to complete disability. A negative change value represents a perceived improvement in ocular health. Both eyes contributed to the mean.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Age 18 years and older of any gender or race

  2. Provision of written informed consent prior to study participation

  3. Willingness and ability to return for all study visits

  4. A positive history of self-reported dry eye symptoms for three months prior to the study using the Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire, and a score of > 6.

  5. Need for regular use of artificial tears, lubricants, or rewetting drops in both eyes

  6. Evidence of meibomian gland (MG) obstruction, based on a total meibomian gland secretion score of < 12 out of a maximum score of 45, for 15 glands (5 nasal, 5 medial, 5 temporal) of the lower eyelid of each eye. Glands expressed & graded from 0 to 3 (0 = no secretion, 1 = inspissated, 2 = cloudy, 3 = clear liquid).

Exclusion Criteria:
  1. History of ocular surgery including intraocular, oculo-plastic, corneal or refractive surgery within 1 year

  2. Ocular trauma or herpetic keratitis within the previous 3 months

  3. Cicatricial lid margin disease identified via slit lamp examination, including pemphigoid, symblepharon, etc.

  4. Active ocular infection (e.g., viral, bacterial, mycobacterial, protozoan, or fungal infection of the cornea, conjunctiva, lacrimal gland, lacrimal sac, or eyelids including a hordeolum or stye)

  5. Active ocular inflammation or history of chronic, recurrent ocular inflammation within prior 3 months (e.g. retinitis, macular inflammation, choroiditis, uveitis, iritis, scleritis, episcleritis, keratitis)

  6. Ocular surface abnormality that may compromise corneal integrity (e.g., prior chemical burn, recurrent corneal erosion, corneal epithelial defect, Grade 3 corneal fluorescein staining, or map dot fingerprint dystrophy

  7. Lid surface abnormalities (e.g., entropion, ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis) that affect lid function in either eye

  8. Anterior blepharitis (staphylococcal, demodex or seborrheic grade 3 or 4)

  9. Ocular trauma, chemical burns, or limbal stem cell deficiency

  10. Systemic disease conditions that cause dry eye (e.g., Stevens-Johnson syndrome, vitamin A deficiency, rheumatoid arthritis, Wegener's granulomatosis, sarcoidosis, leukemia, Riley-Day syndrome, systemic lupus erythematosus, Sjogren's syndrome)

  11. Women who are pregnant, nursing, or not utilizing adequate birth control measures

  12. Individuals who have either changed the dosing of systemic or ophthalmic medication within the past 30 days prior to screening or who are unable or unwilling to remain on a stable dosing regimen for the duration of the study

  13. Individuals using isotretinoin (Accutane) within 1 year, cyclosporine-A (Restasis) within 2 months, or topical medications other than non-preserved artificial tears within 2 weeks.

  14. Individuals using another investigational device or agent within 30 days of study participation

  15. Contact lens wearers or individuals who have worn contact lenses in the last 30 days or anticipate wearing contact lenses during this study.

Contacts and Locations

Locations

SiteCityStateCountryPostal Code
1TearFilm Investigative SiteEncinitasCaliforniaUnited States92924
2TearFilm Investigative SiteSan DiegoCaliforniaUnited States92122
3TearFilm Investigative SiteSan DiegoCaliforniaUnited States92128

Sponsors and Collaborators

  • Tear Film Innovations, Inc.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Tear Film Innovations, Inc.
ClinicalTrials.gov Identifier:
NCT03055650
Other Study ID Numbers:
  • 2020-01
First Posted:
Feb 16, 2017
Last Update Posted:
Nov 12, 2020
Last Verified:
Oct 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Tear Film Innovations, Inc.
Additional relevant MeSH terms:

Study Results

Participant Flow

Recruitment DetailsParticipants were recruited from 3 investigative sites located in the United States.
Pre-assignment DetailThis reporting group includes all enrolled participants.
Arm/Group TitleiLux 2020 System
Arm/Group DescriptionMeibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual
Period Title: Overall Study
STARTED30
COMPLETED30
NOT COMPLETED0

Baseline Characteristics

Arm/Group TitleiLux 2020 System
Arm/Group DescriptionMeibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual
Overall Participants30
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]
52.9
(11.9)
Sex: Female, Male (Count of Participants)
Female
20
66.7%
Male
10
33.3%
Race/Ethnicity, Customized (participants) [Number]
White
20
66.7%
Native American
4
13.3%
Asian
2
6.7%
Hispanic
2
6.7%
Other
1
3.3%
Region of Enrollment (participants) [Number]
United States
30
100%

Outcome Measures

1. Primary Outcome
TitleChange From Baseline in Meibomian Gland Secretion (MGS) Total Score
DescriptionMeibomian glands on the lower eyelid were assessed by the examiner using a Meibomian Gland Evaluator (MGE 1000) device while viewing the eyelid margin with a slit lamp microscope. 5 glands in 3 zones (nasal, medial, temporal) were evaluated. Each gland was scored from 0-3, for a resultant overall score of 0-45 for each eye. MGS scoring was as follows: 0 = no secretion (worst), 1 = inspissated, 2 = cloudy, 3 = clear liquid (best). A positive change value indicates an improvement. Eyes were assessed individually.
Time FrameBaseline (Day 0 pretreatment), Week 1, Month 1

Outcome Measure Data

Analysis Population Description
All treated with available data
Arm/Group TitleiLux 2020 System
Arm/Group DescriptionMeibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual
Measure Participants30
Measure eyes60
Change from Baseline at Week 1
12.3
(7.1)
Change from Baseline at Month 1
14.5
(7.9)
Statistical Analysis 1
Statistical Analysis Overview Comparison Group Selection iLux 2020 System
Comments Change from Baseline in Meibomian Gland Secretion Total Score at Week 1
Type of Statistical Test Superiority
Comments
Statistical Test of Hypothesisp-Value<0.0001
Comments
Methodt-test, 2 sided
CommentsStatistical significance is set at α = 0.05.
Statistical Analysis 2
Statistical Analysis Overview Comparison Group Selection iLux 2020 System
Comments Change from Baseline in Meibomian Gland Secretion Total Score at Month 1
Type of Statistical Test Superiority
Comments
Statistical Test of Hypothesisp-Value<0.0001
Comments
Methodt-test, 2 sided
CommentsStatistical significance is set at α = 0.05.
2. Primary Outcome
TitleChange From Baseline in Tear Break-Up Time (TBUT)
DescriptionThe investigator instilled a drop of fluorescein into the lower eyelid and asked the patient to blink several times, then stop. The time between the last blink and the first appearance of a dark spot on the cornea (formation of a dry area) on the otherwise continuously stained tear film was recorded in seconds. 3 consecutive measurements were taken, with TBUT defined as the average of the 3 measurements. A positive change value represents A positive change value represents a more stable tear film (improvement). Eyes were assessed individually.
Time FrameBaseline (Day 0 pretreatment), Week 1, Month 1

Outcome Measure Data

Analysis Population Description
All treated with available data
Arm/Group TitleiLux 2020 System
Arm/Group DescriptionMeibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual
Measure Participants30
Measure eyes60
Change from Baseline at Week 1
3.6
(3.1)
Change from Baseline at Month 1
4.6
(3.1)
Statistical Analysis 1
Statistical Analysis Overview Comparison Group Selection iLux 2020 System
Comments Change From Baseline in Tear Break-Up Time (TBUT) at Week 1
Type of Statistical Test Superiority
Comments
Statistical Test of Hypothesisp-Value<0.0001
Comments
Methodt-test, 2 sided
CommentsStatistical significance is set at α = 0.05.
Statistical Analysis 2
Statistical Analysis Overview Comparison Group Selection iLux 2020 System
Comments Change From Baseline in Tear Break-Up Time (TBUT) at Month 1
Type of Statistical Test Superiority
Comments
Statistical Test of Hypothesisp-Value<0.0001
Comments
Methodt-test, 2 sided
CommentsStatistical significance is set at α = 0.05.
3. Secondary Outcome
TitleChange From Baseline in Standard Patient Evaluation of Eye Dryness (SPEED) Total Score
DescriptionThe Standard Patient Evaluation of Eye Dryness (SPEED) survey is a validated survey that assesses both the frequency and severity of dry eye symptoms. The patient grades the frequency of symptoms (4 items) on a scale from 0 to 3 (0=never; 3=constant) and the severity of each symptom (4 items) on a scale from 0 to 4 (0=no problems; 4=intolerable). Responses to the 8 items are summed to calculate a total score ranging from 0 to 28, where 0=best and 28=worst. A negative change value indicates a perceived improvement in ocular health. Both eyes contributed to the mean.
Time FrameBaseline (Day 0 pretreatment), Week 1, Month 1

Outcome Measure Data

Analysis Population Description
All treated with available data
Arm/Group TitleiLux 2020 System
Arm/Group DescriptionMeibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual
Measure Participants30
Change from Baseline at Week 1
-8.6
(7.0)
Change from Baseline at Month 1
-9.1
(6.6)
Statistical Analysis 1
Statistical Analysis Overview Comparison Group Selection iLux 2020 System
Comments Change From Baseline in Standard Patient Evaluation of Eye Dryness (SPEED) Total Score at Week 1
Type of Statistical Test Superiority
Comments
Statistical Test of Hypothesisp-Value<0.0001
Comments
Methodt-test, 2 sided
CommentsStatistical significance is set at α = 0.025.
Statistical Analysis 2
Statistical Analysis Overview Comparison Group Selection iLux 2020 System
Comments Change From Baseline in Standard Patient Evaluation of Eye Dryness (SPEED) Total Score at Month 1
Type of Statistical Test Superiority
Comments
Statistical Test of Hypothesisp-Value<0.0001
Comments
Methodt-test, 2 sided
CommentsStatistical significance is set at α = 0.025.
4. Secondary Outcome
TitleChange From Baseline in Ocular Surface Disease Index (OSDI) Total Score
DescriptionThe OSDI is a validated, 12-item questionnaire used to measure ocular symptoms, visual function, and environmental factors that may affect a patient's vision. The patient grades each item on a scale from 0 to 4, where 0 is "None" and 4 is "All of the Time." Responses to the 12 items are summed, and a formula is used to calculate a total score from 0 to 100, where 0 corresponds to no disability and 100 corresponds to complete disability. A negative change value represents a perceived improvement in ocular health. Both eyes contributed to the mean.
Time FrameBaseline (Day 0 pretreatment), Month 1

Outcome Measure Data

Analysis Population Description
All treated with available data
Arm/Group TitleiLux 2020 System
Arm/Group DescriptionMeibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual
Measure Participants30
Mean (Standard Deviation) [score on a scale]
-28.5
(22.0)
Statistical Analysis 1
Statistical Analysis Overview Comparison Group Selection iLux 2020 System
Comments
Type of Statistical Test Superiority
Comments
Statistical Test of Hypothesisp-Value<0.0001
Comments
Methodt-test, 2 sided
CommentsStatistical significance is set at α = 0.025.

Adverse Events

Time FrameAdverse event data was collected for each participant from time of enrollment until time of study exit, approximately 4 weeks.
Adverse Event Reporting Description An adverse event was defined as any untoward and unintended sign, symptom or disease temporally associated with the use of an investigational drug or device, or other protocol-imposed intervention, regardless of the suspected cause. All subjects exposed to the study treatment were evaluated for adverse events.
Arm/Group TitleiLux 2020 System
Arm/Group DescriptionMeibomian Gland Treatment iLux 2020 System: Heating and compression to express clogged meibomian glands
All Cause Mortality
iLux 2020 System
Affected / at Risk (%)# Events
Total0/30 (0%)
Serious Adverse Events
iLux 2020 System
Affected / at Risk (%)# Events
Total0/30 (0%)
Other (Not Including Serious) Adverse Events
iLux 2020 System
Affected / at Risk (%)# Events
Total0/30 (0%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact

Name/TitleSenior CDMA Project Lead, CDMA Ocular Health
OrganizationAlcon Research, LLC
Phone1-888-451-3937
Emailalcon.medinfo@alcon.com
Responsible Party:
Tear Film Innovations, Inc.
ClinicalTrials.gov Identifier:
NCT03055650
Other Study ID Numbers:
  • 2020-01
First Posted:
Feb 16, 2017
Last Update Posted:
Nov 12, 2020
Last Verified:
Oct 1, 2020